Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma

25Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft model of feline mammary carcinoma expressing VEGF protein. Bevacizumab treatment suppressed tumor growth by inhibiting angiogenesis and enhancing apoptosis; however, it did not affect the tumor proliferation index. Thus, bevacizumab had anti-tumor effects on a xenograft model, and this may be useful for the treatment of feline mammary carcinoma.

Cite

CITATION STYLE

APA

Michishita, M., Ohtsuka, A., Nakahira, R., Tajima, T., Nakagawa, T., Sasaki, N., … Takahashi, K. (2016). Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma. Journal of Veterinary Medical Science, 78(4), 685–689. https://doi.org/10.1292/jvms.15-0550

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free